EUVIMEDEUVIMED entdecken
Open Access

Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases

Jian-Hua Zhao, Hsuan-Liang Liu, Hsin-Yi Lin, Chih-Hung Huang, Hsu-Wei Fang, Shiao-Shing Chen, Yih Ho, Wei-Bor Tsai, Wen-Yih Chen

Perspectives in Medicinal Chemistry · 2007

DOI: 10.4137/pmc.s212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Perspectives in Medicinal Chemistry, 2007. Verfasst von Jian-Hua Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering and Biotechnology, National Taipei University of Technology, 1 Sec. 3 ZhongXiao E. Rd., Taipei 10608. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein misfolding and aggregation cause a large number of neurodegenerative diseases in humans due to (i) gain of function as observed in Alzheimer's disease, Huntington's disease, Parkinson's disease, and Prion's disease or (ii) loss of function as observed in cystic fibrosis and α1-antitrypsin deficiency. These misfolded proteins could either lead to the formation of harmful amyloids that become toxic for the cells or to be recognized and prematurely degraded by the protein quality control system. An increasing number of studies has indicated that some low-molecular-weight compounds named as chemical chaperones can reverse the mislocalization and/or aggregation of proteins associated with human conformational diseases. These small molecules are thought to non-selectively stabilize proteins and facilitate their folding. In this review, we summarize the probable mechanisms of protein conformational diseases in humans and the use of chemical chaperones and inhibitors as potential therapeutic agents against these diseases. Furthermore, recent advanced experimental and theoretical approaches underlying the detailed mechanisms of protein conformational changes and current structure-based drug designs towards protein conformational diseases are also discussed. It is believed that a better understanding of the mechanisms of conformational changes as well as the biological functions of these proteins will lead to the development and design of potential interfering compounds against amyloid formation associated with protein conformational diseases.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseHuntington’s diseaseParkinson’s diseasePrion’s diseaseamyloidchemical chaperonemisfoldingmolecular dynamics simulationprotein conformational diseasestructure-based drug design

Autor:innen und Institutionen

  • Department of Chemical Engineering and Biotechnology, National Taipei University of Technology, 1 Sec. 3 ZhongXiao E. Rd., Taipei 10608.

Zitieren

APA

Zhao, J. H., Liu, H. L., Lin, H. Y., Huang, C. H., Fang, H. W., Chen, S. S., Ho, Y., Tsai, W. B., & Chen, W. Y. (2007). Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases. Perspectives in Medicinal Chemistry. https://doi.org/10.4137/pmc.s212

Vancouver

Zhao JH, Liu HL, Lin HY, Huang CH, Fang HW, Chen SS, et al. Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases. Perspectives in Medicinal Chemistry. 2007. doi:10.4137/pmc.s212

BibTeX
@article{Zhao2007,
  author = {Zhao, Jian-Hua and Liu, Hsuan-Liang and Lin, Hsin-Yi and Huang, Chih-Hung and Fang, Hsu-Wei and Chen, Shiao-Shing and Ho, Yih and Tsai, Wei-Bor and Chen, Wen-Yih},
  title = {Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases},
  journal = {Perspectives in Medicinal Chemistry},
  year = {2007},
  doi = {10.4137/pmc.s212}
}
Kostenlos starten →